Medical Pharmacology: ANS Cholinergic Pharmacology — Module 1: Tier 1

Medical Pharmacology Question Bank: ANS Cholinergic Pharmacology — Module 1 | Tier 1 — Foundational Recall

Chapter 6: Cholinergic Pharmacology — Module 1: ACh Synthesis, Storage, Release, and Receptor Physiology
Tier 1 — Foundational Recall

1. Acetylcholine is synthesized in cholinergic nerve terminals by a single enzymatic reaction. Which of the following correctly identifies the enzyme, substrates, and the rate-limiting step in acetylcholine biosynthesis?

A) Acetylcholine is synthesized by acetylcholinesterase (AChE) acting on phosphorylcholine and acetyl-CoA; AChE is present in both synaptic vesicles and the synaptic cleft; the rate-limiting step is delivery of acetyl-CoA from neuronal mitochondria to the vesicular compartment; inhibition of AChE by physostigmine therefore blocks both ACh degradation and synthesis simultaneously.
B) Acetylcholine is synthesized by choline oxidase acting on choline and acetyl-CoA; the enzyme is concentrated in synaptic vesicle membranes; the rate-limiting step is the vesicular uptake of choline by the vesicular acetylcholine transporter (VAChT); vesamicol blocks choline oxidase, depleting ACh stores without affecting vesicular packaging.
C) Acetylcholine is synthesized by choline acetyltransferase (ChAT) from choline and acetyl-CoA, producing ACh and CoA; ChAT is synthesized in the soma and transported to nerve terminals; the rate-limiting step is uptake of choline from the extracellular space by the high-affinity choline transporter (CHT1), which recovers approximately 50% of choline from hydrolyzed ACh; hemicholinium-3 competitively inhibits CHT1, depleting ACh stores without directly inhibiting ChAT or vesicular packaging.
D) Acetylcholine is synthesized by acetyl-CoA carboxylase acting on choline and malonyl-CoA in the neuronal soma; the enzyme product is transported by fast axoplasmic transport to the nerve terminal; the rate-limiting step is the availability of malonyl-CoA derived from fatty acid metabolism; inhibition of acetyl-CoA carboxylase with statins explains the neuromuscular effects seen with this drug class.
E) Acetylcholine is synthesized by choline acetyltransferase from phosphatidylcholine and acetyl-CoA; phosphatidylcholine is cleaved by phospholipase D at the presynaptic membrane to provide choline; the rate-limiting step is phospholipase D activity, which is regulated by nerve terminal firing rate; hemicholinium-3 inhibits phospholipase D rather than the choline transporter.

ANSWER: C

Rationale:

ChAT catalyzes the transfer of the acetyl group from acetyl-CoA to choline — a single-step cytoplasmic reaction in cholinergic nerve terminals. ChAT is a reliable immunohistochemical marker of cholinergic neurons because it is specific to these cells. Acetyl-CoA is derived predominantly from mitochondrial pyruvate oxidation. The true rate-limiting step is choline availability, determined by CHT1 (SLC5A7), a sodium-dependent high-affinity transporter on the presynaptic plasma membrane. Approximately 50% of synaptic choline liberated by AChE-mediated ACh hydrolysis is recovered by CHT1 — a critical recycling mechanism. CHT1 activity is regulated by neuronal firing: increased demand traffics more CHT1 to the plasma membrane. Hemicholinium-3 (HC-3 [high-affinity choline uptake inhibitor]) competitively blocks CHT1, progressively depleting ACh stores as existing vesicular ACh is released but cannot be replenished — a pharmacological tool demonstrating that transport, not ChAT activity itself, limits synthesis. Options A, B, D, and E all misidentify either the enzyme, substrate, rate-limiting step, or inhibitor mechanism.

Option A: Option A is incorrect: ACh is not synthesized by acetylcholinesterase (AChE); AChE hydrolyzes ACh — it is the degradative enzyme, not the synthetic enzyme; the synthetic enzyme is choline acetyltransferase (ChAT); additionally, AChE is located in the synaptic cleft and postsynaptic membrane, not in synaptic vesicles.
Option B: Option B is incorrect: ACh is not synthesized by choline oxidase; choline oxidase is an enzyme in bacteria and plants that oxidizes choline to betaine; it has no role in mammalian ACh synthesis; the synthetic enzyme is ChAT, which performs an acetyltransferase reaction (not an oxidation) combining choline with acetyl-CoA.
Option D: Option D is incorrect: ACh is not synthesized by acetyl-CoA carboxylase; acetyl-CoA carboxylase is the enzyme that carboxylates acetyl-CoA to malonyl-CoA in fatty acid synthesis, a completely different metabolic pathway; additionally, ACh synthesis occurs in the nerve terminal cytoplasm (where ChAT resides), not in the neuronal soma.
Option E: Option E is incorrect: ACh synthesis does not use phosphatidylcholine as the choline source for the ChAT reaction; while phospholipase D does cleave phosphatidylcholine (producing choline as a byproduct), the primary choline source for ACh synthesis is reuptake of choline from the synaptic cleft via CHT1, not phosphatidylcholine hydrolysis; the CHT1 supply is the rate-limiting step.

2. Acetylcholine is packaged into synaptic vesicles by a specific vesicular transporter. Which of the following correctly identifies this transporter, its pharmacological inhibitor, and the consequence of inhibition?

A) Vesicular ACh packaging is carried out by the vesicular monoamine transporter 2 (VMAT2) in cholinergic terminals; VMAT2 uses the proton electrochemical gradient across the vesicular membrane to drive ACh import; reserpine irreversibly inhibits VMAT2, depleting both monoamine and ACh vesicular stores simultaneously, which explains the profound bradycardia seen with reserpine in clinical use.
B) Vesicular ACh packaging is mediated by CHT1 translocated from the plasma membrane into vesicular membranes during endocytosis; when CHT1 is internalized it repackages ACh from the cytoplasm back into vesicles; hemicholinium-3 therefore depletes vesicular ACh by blocking both plasma membrane uptake and vesicular recycling at the same CHT1 molecule.
C) Vesicular ACh packaging is carried out by the vesicular glutamate transporter (VGLUT) isoform expressed in cholinergic neurons; VGLUT uses an ATP-dependent mechanism to concentrate ACh approximately 1000-fold relative to cytoplasmic levels; vesamicol blocks VGLUT selectively in cholinergic terminals, depleting ACh stores without affecting glutamate release from other neurons.
D) Vesicular ACh packaging is carried out by the vesicular acetylcholine transporter (VAChT, encoded by SLC18A3), which uses the proton electrochemical gradient established by a V-type H⁺-ATPase across the vesicular membrane to exchange luminal protons for cytoplasmic ACh; vesamicol blocks VAChT, preventing ACh loading into vesicles so that newly synthesized ACh accumulates in the cytoplasm and is eventually hydrolyzed; VAChT inhibition depletes vesicular ACh stores while leaving synthesis and uptake pathways intact.
E) Vesicular ACh packaging is carried out by an ATP-binding cassette (ABC) transporter on the vesicular membrane that requires ATP hydrolysis directly to concentrate ACh; vesamicol acts as a competitive substrate for this ABC transporter, occupying the ACh binding site without being transported; the result is competitive inhibition that can be overcome by increasing cytoplasmic ACh concentration through AChE inhibitor administration.

ANSWER: D

Rationale:

VAChT (vesicular acetylcholine transporter, gene SLC18A3) is the dedicated transporter for ACh packaging into synaptic vesicles. It is a proton antiporter — the V-type H⁺-ATPase on the vesicular membrane pumps protons into the vesicle lumen, generating an electrochemical gradient (acidic, positive interior). VAChT uses this gradient to exchange one luminal proton for one cytoplasmic ACh molecule, concentrating ACh inside vesicles. Vesamicol is a non-competitive inhibitor of VAChT; it binds to an allosteric site distinct from the ACh translocation site, blocking the transporter without direct competition with ACh. Vesamicol inhibition causes progressive depletion of vesicular ACh as release continues but loading cannot occur. Option E mischaracterizes the transporter as an ABC-type and incorrectly implies competitive kinetics reversible by AChE inhibitors.

Option A: Option A incorrectly assigns packaging to VMAT2 (which handles monoamines, not ACh).
Option B: Option B incorrectly relocates CHT1 function to vesicles.
Option C: Option C incorrectly attributes packaging to VGLUTs.
Option E: Option E is incorrect: VAChT is not an ATP-binding cassette (ABC) transporter; VAChT is a proton-antiporter that belongs to the major facilitator superfamily (MFS); it uses the proton electrochemical gradient across the vesicular membrane to drive ACh uptake into vesicles (H+ out, ACh in); ABC transporters use direct ATP hydrolysis, which is not VAChT's mechanism; additionally, vesamicol is not a competitive inhibitor — it binds to a distinct site outside the ACh transport pathway.

3. Acetylcholine exocytosis from cholinergic nerve terminals is triggered by calcium influx. Which of the following most accurately describes the calcium-dependent mechanism of ACh exocytosis and identifies a toxin that exploits this mechanism?

A) Calcium entering through voltage-gated L-type (Cav1) channels directly phosphorylates SNARE proteins, producing a conformational change that fuses the vesicular membrane with the plasma membrane; botulinum toxin blocks the L-type calcium channel pore, preventing calcium entry and thereby abolishing ACh exocytosis without degrading SNARE proteins.
B) Depolarization of the terminal opens voltage-gated N-type calcium channels; calcium binds calmodulin, activating calmodulin-dependent kinase II (CaMKII) which phosphorylates synapsin I, releasing vesicles from the cytoskeletal reserve pool; Lambert-Eaton myasthenic syndrome involves autoantibodies against CaMKII, preventing vesicular mobilization and causing the proximal muscle weakness characteristic of the syndrome.
C) Calcium entering through P/Q-type channels activates phospholipase C, which cleaves PIP₂ into IP₃ and DAG; IP₃ releases calcium from the smooth endoplasmic reticulum of the nerve terminal, providing the bulk of the calcium signal for exocytosis; DAG activates protein kinase C which phosphorylates synaptotagmin, triggering SNARE complex assembly and vesicle fusion.
D) Calcium binds to synaptobrevin on the vesicular membrane, driving a spontaneous SNARE complex formation between synaptobrevin, SNAP-25, and syntaxin; the resulting force pulls the vesicular and plasma membranes together; tetanus toxin cleaves syntaxin on the presynaptic plasma membrane, selectively blocking ACh release at the neuromuscular junction while sparing GABAergic inhibitory interneuron terminals in the spinal cord.
E) Depolarization of the nerve terminal opens voltage-gated P/Q-type (Cav2.1) calcium channels; calcium binds synaptotagmin I on the vesicular membrane, which acts as the calcium sensor and triggers rapid SNARE complex zippering between vesicular synaptobrevin (VAMP) and plasma membrane SNAP-25 and syntaxin 1; this drives membrane fusion and ACh exocytosis; Lambert-Eaton myasthenic syndrome is caused by autoantibodies against Cav2.1 channels, reducing calcium influx and impairing ACh release, producing proximal muscle weakness that transiently improves with repeated activity.

ANSWER: E

Rationale:

ACh exocytosis is a calcium-dependent process initiated by action potential-driven depolarization of the presynaptic terminal. The relevant calcium channels at the NMJ and many central cholinergic synapses are voltage-gated P/Q-type (Cav2.1) channels. Calcium entering through these channels binds synaptotagmin I — the principal calcium sensor on synaptic vesicles — triggering a conformational change that promotes SNARE complex assembly: synaptobrevin (VAMP, on the vesicle) zippers with SNAP-25 and syntaxin 1 (on the plasma membrane), generating the mechanical force for membrane fusion. Lambert-Eaton myasthenic syndrome (LEMS) is caused by IgG autoantibodies targeting Cav2.1, reducing calcium influx per action potential; repetitive stimulation allows calcium accumulation and transiently improves neuromuscular transmission — the pathognomonic incremental response to repetitive nerve stimulation.

Option A: Option A incorrectly assigns calcium entry to L-type channels and incorrectly describes botulinum toxin's mechanism.
Option B: Option B incorrectly attributes LEMS to anti-CaMKII antibodies.
Option C: Option C incorrectly invokes PLC-IP₃ signaling as the principal calcium amplification mechanism for fast exocytosis.
Option D: Option D incorrectly assigns the calcium sensor role to synaptobrevin and misidentifies tetanus toxin's targets and specificity.

4. Acetylcholine released into the synapse is hydrolyzed by acetylcholinesterase. Which of the following correctly describes the catalytic mechanism of AChE, its location, and the clinically important distinction between AChE and butyrylcholinesterase?

A) AChE hydrolyzes ACh via a two-step serine hydrolase mechanism: acylation — the active-site serine (Ser203) performs nucleophilic attack on the ACh carbonyl, releasing choline and forming a covalent acetyl-serine intermediate — followed by deacylation, in which water hydrolyzes the acetyl-serine bond, releasing acetate and regenerating active enzyme; AChE is concentrated in the synaptic cleft (collagen-anchored ColQ form at the NMJ) and on erythrocytes; butyrylcholinesterase (BuChE, pseudocholinesterase) is present in plasma and liver, hydrolyzes succinylcholine and mivacurium (but not ACh efficiently), and lacks a functional role in terminating synaptic ACh — its clinical importance lies in metabolism of drugs like succinylcholine and its genetic deficiency causing prolonged neuromuscular blockade.
B) AChE hydrolyzes ACh by a histidine-dependent proton relay without covalent intermediate formation; ACh is degraded by a concerted mechanism in the active site; AChE is located exclusively in the synaptic vesicle lumen, hydrolyzing ACh before it is released to prevent spontaneous exocytosis; BuChE is the enzyme responsible for synaptic ACh termination in the peripheral nervous system because AChE is too slow to terminate transmission on its own.
C) AChE uses an active-site tyrosine residue to form a covalent phenol-ACh intermediate; choline is released in the first step and acetate in the second; AChE is located only in the postsynaptic membrane; BuChE is the form present in the synaptic cleft at the NMJ and is responsible for the majority of synaptic ACh hydrolysis; genetic BuChE deficiency primarily causes reduced cholinergic tone rather than drug sensitivity.
D) AChE hydrolyzes ACh and butyrylcholine equally efficiently; it is present in high concentrations in plasma and is responsible for succinylcholine hydrolysis; AChE genetic polymorphisms cause prolonged apnea after succinylcholine administration; BuChE is the neuronal form confined to cholinergic terminals and is the rate-limiting enzyme for ACh synthesis rather than degradation.
E) AChE is a serine protease that hydrolyzes ACh via the same catalytic triad used by trypsin; it requires calcium as a cofactor for full catalytic activity; at the NMJ, AChE is exclusively located on the presynaptic terminal; BuChE has identical substrate specificity to AChE but a slower turnover rate; organophosphate sensitivity is determined entirely by AChE genotype and not by BuChE activity.

ANSWER: A

Rationale:

AChE operates through a classic serine hydrolase mechanism. The catalytic triad (Ser203, His447, Glu334) enables nucleophilic catalysis: the serine attacks the electrophilic carbonyl of ACh, releasing choline and forming a covalent acetyl-serine intermediate (acylation); water then attacks this intermediate, releasing acetate and regenerating free enzyme (deacylation). The turnover rate is extraordinarily fast (~10,000 molecules/sec), among the highest of any enzyme. AChE is positioned precisely in the synaptic cleft — at the NMJ, it is anchored to the basal lamina via the structural protein ColQ (collagen-tailed form); it is also present on erythrocyte membranes and in brain. BuChE (pseudocholinesterase, plasma cholinesterase) is synthesized by the liver and circulates in plasma; it efficiently hydrolyzes succinylcholine, mivacurium, aspirin, and heroin, but plays no significant role in synaptic ACh termination. BuChE deficiency (dibucaine-resistant variants) causes prolonged succinylcholine apnea — a clinically important pharmacogenomic interaction. Options B through E all contain errors about enzyme location, mechanism, or substrate specificity.

Option B: Option B is incorrect: AChE does not use a histidine-dependent proton relay without covalent intermediate; AChE specifically uses a serine-histidine-glutamate catalytic triad where the serine residue forms a covalent acyl-enzyme intermediate (acetyl-serine) during hydrolysis; a histidine-only mechanism without covalent intermediate would describe a different type of protease; the covalent serine intermediate is the basis for organophosphate (serine alkylation) and carbamylating agent (serine carbamylation) mechanisms.
Option C: Option C is incorrect: AChE does not use an active-site tyrosine residue to form a phenol-ACh intermediate; the active-site nucleophile is serine (Ser-200 in Torpedo AChE), not tyrosine; additionally, AChE is not located exclusively on the postsynaptic membrane — it is found in both the synaptic cleft (anchored by ColQ) and on the postsynaptic membrane, and also intracellularly in neurons.
Option D: Option D is incorrect: AChE does not hydrolyze butyrylcholine efficiently — BuChE (pseudocholinesterase) hydrolyzes butyrylcholine; AChE and BuChE differ in substrate specificity; AChE specifically cleaves ACh and some other acetyl esters but has low butyrylcholinesterase activity; additionally, succinylcholine hydrolysis in plasma is performed by BuChE, not AChE; AChE genetic polymorphisms do not cause prolonged succinylcholine block — that is BuChE pharmacogenomics.
Option E: Option E is incorrect: AChE is not a serine protease in the classical sense (it belongs to the serine hydrolase family but is structurally distinct from trypsin-like serine proteases); more importantly, AChE does not require calcium as a cofactor — it is a calcium-independent enzyme; additionally, AChE at the NMJ is both extracellular (cleft-anchored via ColQ) and on the postsynaptic membrane, not exclusively extracellular.

5. Muscarinic acetylcholine receptors are GPCRs classified into five subtypes. Which of the following correctly pairs the muscarinic receptor subtypes with their G-protein coupling and primary signaling pathways?

A) M1, M2, and M3 all couple to Gαq, activating phospholipase C to generate IP₃ and DAG; M4 and M5 couple to Gαs, activating adenylyl cyclase and increasing cAMP; M2 receptors are responsible for the positive chronotropic effect of parasympathetic stimulation of the heart through Gαq-mediated PKC activation and L-type calcium channel opening.
B) All five muscarinic receptor subtypes (M1–M5) couple exclusively to Gαi, inhibiting adenylyl cyclase and reducing cAMP in all tissues; the apparent excitatory effects of muscarinic stimulation in smooth muscle and glands are mediated by post-receptor cAMP-independent pathways rather than PLC activation; M3-mediated glandular secretion and smooth muscle contraction are cAMP-independent phenomena not involving IP₃.
C) M1, M3, and M5 couple to Gαq, activating phospholipase Cβ to generate IP₃ (releasing intracellular Ca²⁺) and DAG (activating PKC); M2 and M4 couple to Gαi/o, inhibiting adenylyl cyclase (reducing cAMP) and activating inward rectifier potassium channels (GIRK) via Gβγ subunits; M2 cardiac receptors produce negative chronotropy and dromotropy through Gαi-mediated reduction of I_f current and Gβγ-mediated GIRK activation causing membrane hyperpolarization.
D) M1 and M4 couple to Gαq; M2, M3, and M5 couple to Gαs; the dominant muscarinic effect on the heart is M3-mediated cAMP increase producing positive inotropy; M2 receptors are expressed in smooth muscle and are responsible for bronchospasm; M1 receptors in the CNS mediate the sedative effects of central muscarinic stimulation through Gαq-driven inhibition of neuronal firing.
E) M1 couples to Gαq in the CNS; M2 couples to Gαi in the heart; M3 couples to Gαs in smooth muscle and glands, activating adenylyl cyclase and increasing cAMP to drive secretion; the result is that M3 agonists like bethanechol increase glandular secretions through cAMP-PKA activation of secretory cells, rather than through calcium-dependent mechanisms.

ANSWER: C

Rationale:

Muscarinic receptors follow an alternating G-protein coupling pattern that underlies their distinct physiological effects. Odd-numbered subtypes (M1, M3, M5) couple to Gαq → activate PLCβ → IP₃ (Ca²⁺ release from ER) + DAG (PKC activation) → excitatory effects in smooth muscle, glands, and CNS. Even-numbered subtypes (M2, M4) couple to Gαi/o → inhibit adenylyl cyclase (↓cAMP) and release Gβγ subunits that directly activate inward rectifier K⁺ channels (IKACh/GIRK). At the SA and AV nodes, M2 activation reduces the pacemaker I_f current (via ↓cAMP) and hyperpolarizes the membrane through GIRK channels → negative chronotropy and dromotropy. M3 in smooth muscle and glands drives contraction and secretion via IP₃-Ca²⁺. These coupling differences explain why muscarinic effects can be both inhibitory (heart, via M2) and excitatory (smooth muscle, glands, via M3) from the same parasympathetic transmitter. Options A, B, D, and E all misassign G-protein couplings or misattribute physiological effects to wrong receptor subtypes.

Option A: Option A is incorrect: M1 and M2 do not both couple to Gαq; M1 (and M3, M5) couples to Gαq, while M2 (and M4) couples to Gαi — this Gαi coupling explains M2's cardiac effects (negative chronotropy via GIRK activation, not positive inotropy); additionally, M4 and M5 do not couple to Gαs — M4 couples to Gαi like M2, and M5 also couples to Gαq like M1/M3.
Option B: Option B is incorrect: all five muscarinic receptor subtypes do not couple exclusively to Gαi; M1, M3, and M5 couple to Gαq (producing IP3-DAG signaling and excitatory effects), while only M2 and M4 couple to Gαi; the Gαq-coupled subtypes produce many of the excitatory autonomic effects (glandular secretion, smooth muscle contraction) that are clearly not consistent with Gαi-mediated cAMP inhibition.
Option D: Option D is incorrect: M1 and M4 do not couple to Gαq; M4 couples to Gαi (like M2), not Gαq; additionally, M3 (not M2) mediates salivary and glandular secretion via Gαq, and M2 (not M3) mediates negative chronotropy in the heart; describing M2 cardiac effects as "M3-mediated cAMP increase producing positive inotropy" is doubly wrong — cardiac sympathetic positive inotropy is beta-1 mediated, and M3 does not produce cardiac positive inotropy.
Option E: Option E is incorrect: M3 does not couple to Gαs in smooth muscle; M3 couples to Gαq, activating PLC-IP3-Ca2+ signaling to produce smooth muscle contraction and glandular secretion (not Gαs-cAMP elevation); Gαs-mediated receptor signaling in smooth muscle (like β2 adrenoceptors) typically produces relaxation, not the contraction mediated by M3.

6. Nicotinic acetylcholine receptors (nAChRs) are ligand-gated ion channels with distinct subunit compositions at different anatomical sites. Which of the following correctly identifies the subunit composition and pharmacological properties of the major clinically relevant nAChR populations?

A) The neuromuscular junction nAChR in adult skeletal muscle contains α1, β1, γ, and δ subunits in a 2:1:1:1 stoichiometry; the ganglionic nAChR contains α3 and β4 subunits; CNS nAChRs are exclusively homomeric α7 receptors; all three populations are equally sensitive to curare-type competitive antagonists and are equally blocked by succinylcholine, with the only difference being the location of expression.
B) The adult NMJ nAChR is a pentameric channel with stoichiometry (α1)₂β1δε (replacing γ of the fetal form with ε postnatally); it is blocked competitively by non-depolarizing NMBs (rocuronium, vecuronium) and depolarized by succinylcholine causing Phase I block; ganglionic nAChRs are predominantly α3β4-containing heteromers with some α3β2; CNS nAChRs include heteromeric α4β2 (high-affinity, major target of nicotine addiction) and homomeric α7 (low-affinity, high calcium permeability, important in cognition and schizophrenia); selective blockade of ganglionic vs NMJ receptors can be achieved pharmacologically due to subunit differences.
C) Both NMJ and ganglionic nAChRs contain identical (α4)₂(β2)₃ subunit compositions; the pharmacological difference between NMJ and ganglionic blockade is determined entirely by the lipophilicity of the blocking agent rather than receptor subunit composition; hexamethonium preferentially blocks NMJ receptors while tubocurarine selectively blocks ganglionic receptors due to their different hydrophobicities.
D) Adult NMJ nAChRs contain only α subunits arranged as homomeric (α1)₅ pentamers; they are selectively activated by succinylcholine but not by nicotine; ganglionic nAChRs are heteromeric with α3 and β2 subunits and are selectively blocked by succinylcholine; the CNS lacks functional nAChRs in adults, which is why nicotine must be converted to cotinine to produce its central effects through non-nicotinic receptors.
E) The fetal and adult NMJ nAChRs share identical subunit composition (α1β1γδ); no postnatal subunit switching occurs in healthy humans; γ-to-ε subunit replacement is a pathological change seen only in denervated muscle in ALS; the clinical pharmacology of NMBs is therefore identical between neonates and adults, with no dosing adjustment needed for age-related receptor composition differences.

ANSWER: B

Rationale:

The nAChR family shows important subunit composition differences across anatomical sites, with direct pharmacological consequences. At the adult NMJ: the pentameric receptor has stoichiometry (α1)₂β1δε — two α1 subunits (each contributing one ACh binding site), one each β1, δ, and ε. The fetal form has γ instead of ε; γ→ε replacement occurs postnatally and confers different channel conductance and kinetics. Non-depolarizing NMBs (rocuronium, vecuronium, pancuronium) competitively block ACh at the α1-δ and α1-ε interfaces. Succinylcholine is an ACh-mimic that persistently depolarizes the junction (Phase I block), then in some contexts produces desensitization block (Phase II). Ganglionic nAChRs are predominantly α3β4-containing, with additional α3β2 contributions — pharmacologically distinct, being less sensitive to classic NMJ-blocking agents but blocked by hexamethonium and mecamylamine. CNS nAChRs: α4β2 heteromers are the primary target of nicotine's addictive effects (high affinity, widespread cortical/subcortical expression); α7 homomers are highly calcium-permeable, low-affinity, fast-desensitizing receptors important in cognition and attention. Options A, C, D, and E contain errors in subunit composition, pharmacological selectivity, or developmental biology of nAChRs.

Option A: Option A is incorrect: the adult NMJ nAChR does not contain γ subunits — the γ subunit is present in the fetal isoform and is replaced by the ε subunit postnatally; the adult NMJ nAChR composition is α1₂β1δε (2 alpha-1, 1 beta-1, 1 delta, 1 epsilon); additionally, ganglionic nAChRs are not exclusively α3β4 — multiple subunit combinations exist (including α3β2, α7 homomers) depending on the ganglion.
Option C: Option C is incorrect: NMJ and ganglionic nAChRs do not have identical (α4)₂(β2)₃ subunit compositions; this composition describes the predominant CNS nicotinic receptor (the high-affinity nicotine binding site); the NMJ receptor contains α1, β1, δ, and ε subunits (all type-1 subunits not found in ganglionic receptors), while ganglionic receptors contain type-3 subunits (α3, β4, etc.); the pharmacological differences are determined by subunit composition, not lipophilicity.
Option D: Option D is incorrect: adult NMJ nAChRs are not homomeric (α1)₅ pentamers — homomeric (α7)₅ pentamers are found in the CNS and ganglia; NMJ receptors are heteropentamers with the specific α1₂β1δε composition; additionally, NMJ receptors are activated by nicotine and succinylcholine, and fetal-to-adult γ-to-ε subunit switching is a normal developmental process (not pathological).
Option E: Option E is incorrect: fetal and adult NMJ nAChRs do not share identical subunit composition; the fetal receptor contains α1₂β1γδ while the adult contains α1₂β1εδ — the γ-to-ε subunit switch is a normal postnatal developmental process driven by neural activity that occurs within weeks of birth; this subunit change shifts channel kinetics (faster, briefer openings in the adult ε-containing receptor) and is clinically relevant to understanding certain NMJ pathologies.

7. At the neuromuscular junction, acetylcholine produces muscle contraction through a defined sequence of events. Which of the following correctly describes the complete pharmacodynamic sequence from ACh release to muscle contraction, and identifies where curare-type drugs interrupt this sequence?

A) ACh released from the motor nerve terminal binds to nicotinic receptors on the Schwann cell sheath surrounding the terminal; this activates a cAMP cascade that triggers calcium release from Schwann cell stores; calcium then diffuses to the motor endplate and activates the ryanodine receptor in the sarcoplasmic reticulum; non-depolarizing NMBs block nicotinic receptors on the Schwann cell, preventing signal transduction to the SR.
B) ACh binds to M3 muscarinic receptors on the skeletal muscle endplate, activating Gαq-PLC-IP₃ signaling, releasing calcium from the sarcoplasmic reticulum and activating myosin light-chain kinase; the resulting smooth muscle-like contraction of skeletal muscle is terminated when IP₃ is phosphorylated to IP₄; curare blocks M3 receptors at the endplate, preventing this IP₃-mediated contraction.
C) ACh binds to nAChRs at the endplate, opening the channel and allowing Na⁺ and Ca²⁺ influx; the resulting end-plate potential directly triggers sarcoplasmic reticulum calcium release through ryanodine receptors without involving voltage-gated calcium channels; succinylcholine produces muscle relaxation by activating nAChRs so strongly that they permanently desensitize before any contraction can occur; tubocurarine produces relaxation by activating nAChRs with very low efficacy.
D) ACh binds to nAChRs at the motor endplate, opening the non-selective cation channel to allow Na⁺ (and some Ca²⁺) influx, generating the end-plate potential (EPP); if the EPP exceeds threshold, voltage-gated Na⁺ channels in the perijunctional membrane propagate an action potential along the sarcolemma and into T-tubules, activating Cav1.1 (dihydropyridine receptors) which couple mechanically to ryanodine receptor 1 (RyR1) in the sarcoplasmic reticulum, releasing calcium for actin-myosin cross-bridging; non-depolarizing NMBs competitively block ACh at the nAChR α1 subunit binding sites, preventing EPP generation and thereby preventing the entire downstream cascade.
E) ACh binds to nAChRs at the endplate, but the channel is normally closed even after ACh binding; the actual signal for contraction is the presynaptic motor neuron simultaneously releasing calcitonin gene-related peptide (CGRP) which acts on postsynaptic CGRP receptors to open voltage-gated calcium channels; non-depolarizing NMBs block the CGRP receptor, not the nAChR, which is why they are called neuromuscular blocking agents rather than nicotinic antagonists.

ANSWER: D

Rationale:

The NMJ transmission sequence is a critical pharmacodynamic framework for understanding neuromuscular blocking drugs. The complete sequence: (1) ACh binds the (α1)₂β1δε nAChR at the motor endplate → opens the non-selective cation channel → Na⁺ influx (primarily) generates the EPP; (2) EPP depolarization spreads to the perijunctional sarcolemma → activates voltage-gated Nav1.4 channels → propagates a muscle action potential along the sarcolemma and into T-tubules; (3) T-tubule depolarization activates Cav1.1 (DHPR [dihydropyridine receptor], voltage sensor) → conformational coupling to RyR1 on the terminal cisternae of the SR → Ca²⁺ release into the myoplasm; (4) Ca²⁺ binds troponin C → tropomyosin displacement → actin-myosin cross-bridging → contraction. Non-depolarizing NMBs (rocuronium, vecuronium, tubocurarine) are competitive antagonists at the ACh binding sites on the α1 subunits. By preventing ACh binding, they prevent EPP generation — and without an EPP, no action potential, no T-tubule depolarization, no SR calcium release, no contraction. Succinylcholine, by contrast, persistently activates nAChRs causing sustained depolarization and repolarization failure (Phase I depolarizing block). Options A, B, C, and E all contain fundamental errors in receptor type, signal transduction mechanism, or NMB pharmacology.

Option A: Option A is incorrect: ACh does not bind to nicotinic receptors on Schwann cells to trigger contraction; ACh released from motor nerve terminals binds to nAChRs on the motor endplate (postsynaptic muscle membrane), not Schwann cells; Schwann cells surround the terminal but are not part of the neuromuscular transmission sequence; additionally, non-depolarizing NMBs compete with ACh at the endplate nAChR, not at Schwann cell receptors.
Option B: Option B is incorrect: ACh does not bind to M3 muscarinic receptors at the skeletal muscle endplate; skeletal muscle neuromuscular transmission is exclusively mediated by nAChRs (ionotropic receptors), not muscarinic GPCRs; muscarinic M3 receptors mediate smooth muscle contraction and glandular secretion, not skeletal muscle contraction; non-depolarizing NMBs compete with ACh at nAChRs, not muscarinic receptors.
Option C: Option C is incorrect: while ACh does bind nAChRs and Ca2+ does enter through the channel (contributing to endplate potential), direct SR calcium release through RyR1 does not occur via this mechanism at the NMJ; the EPP triggers muscle fiber action potential propagation along the T-tubule system, which activates the DHPR-RyR1 coupling mechanism (ECMC) — this indirect coupling is distinct from direct Ca2+ influx through the nAChR triggering SR release.
Option E: Option E is incorrect: nAChR channels are not normally closed after ACh binding — ACh binding opens the channel within milliseconds; the primary signal for contraction is not calcitonin gene-related peptide (CGRP) released from the motor neuron; CGRP does have trophic effects on NMJ but is not the primary contractile signal; the established NMJ transmission sequence is: ACh release → nAChR opening → EPP → muscle AP → DHPR → RyR1 → Ca2+ release → contraction.

8. The autonomic nervous system has cholinergic synapses at two distinct anatomical sites: autonomic ganglia and parasympathetic neuroeffector junctions. Which of the following correctly describes the cholinergic pharmacology at each site and explains why ganglionic blockers and muscarinic antagonists have different therapeutic profiles?

A) Autonomic ganglia use muscarinic receptors (M1 type) exclusively for fast transmission; ganglionic blockers like hexamethonium are M1 antagonists; postganglionic parasympathetic transmission uses nicotinic receptors on effector organs; this is why atropine blocks ganglionic transmission while hexamethonium blocks neuroeffector responses; the two drug classes are interchangeable for most clinical purposes.
B) All autonomic ganglia use nicotinic receptors for fast transmission and muscarinic M1 receptors for slow modulation; postganglionic parasympathetic fibers release ACh which acts on M1 receptors exclusively at all effector organs; ganglionic blockers eliminate both sympathetic and parasympathetic outflow equally while muscarinic antagonists only affect parasympathetic neuroeffector junctions; this is why ganglionic blockers cause orthostatic hypotension while muscarinic antagonists do not affect blood pressure significantly.
C) Preganglionic sympathetic fibers release norepinephrine at autonomic ganglia, activating nicotinic receptors; postganglionic parasympathetic fibers release ACh at nicotinic receptors on effector organs; hexamethonium blocks only parasympathetic ganglionic transmission while muscarinic antagonists block only sympathetic postganglionic receptors; this anatomical compartmentalization explains why ganglionic blockers cause bradycardia while muscarinic antagonists cause tachycardia.
D) Autonomic ganglia in both sympathetic and parasympathetic divisions use nicotinic receptors for fast transmission; postganglionic parasympathetic fibers release ACh at muscarinic receptors on effector organs; ganglionic blockers eliminate both autonomic divisions equally while muscarinic antagonists only block parasympathetic neuroeffector responses; this symmetrical ganglionic blockade produces a stereotyped syndrome: tachycardia (from sympathetic cardiac dominance), hypotension (from sympathetic vasomotor blockade), and inhibition of all secretions; muscarinic antagonists produce tachycardia and dry mouth without the hypotension seen with ganglionic blockers.
E) Autonomic ganglia in both sympathetic and parasympathetic divisions use nicotinic receptors (predominantly α3β4-containing) for fast excitatory transmission; postganglionic parasympathetic fibers release ACh onto muscarinic receptors (M2 in heart, M3 in smooth muscle and glands) at neuroeffector junctions; hexamethonium and other ganglionic blockers interrupt both divisions at the ganglionic level, eliminating all autonomic outflow and producing a mixed syndrome including tachycardia (sympathetic tone usually dominates cardiac rate), hypotension, reduced secretions, constipation, and urinary retention; muscarinic antagonists act only at the neuroeffector junction, blocking parasympathetic effects while leaving sympathetic function and ganglionic transmission intact.

ANSWER: E

Rationale:

Understanding the two-tier anatomical organization of the cholinergic autonomic system is fundamental to explaining the pharmacological profiles of ganglionic blockers versus muscarinic antagonists. Both sympathetic and parasympathetic preganglionic fibers release ACh at autonomic ganglia, where α3β4-containing nAChRs mediate fast excitatory postsynaptic potentials (slow modulatory M1 currents also exist but are not the primary transmission mechanism). Postganglionic parasympathetic fibers release ACh at neuroeffector junctions onto M2 receptors (heart — negative chronotropy/dromotropy) and M3 receptors (smooth muscle — contraction; glands — secretion). Ganglionic blockers (hexamethonium, mecamylamine, trimethaphan) block nAChRs at all autonomic ganglia — eliminating both parasympathetic and sympathetic outflow. The resultant physiological effects reflect whichever division normally dominates each organ: heart rate increases (sympathetic normally dominates pacemaker rate in the absence of parasympathetic tone), blood pressure falls (sympathetic vasomotor tone lost), secretions decrease, bowel motility decreases, and bladder relaxes. Muscarinic antagonists act only at the neuroeffector level, blocking parasympathetic end-organ effects without affecting ganglionic transmission or sympathetic function. Options A, B, C, and D all contain errors about receptor types, sites of action, or physiological predictions.

Option A: Option A is incorrect: autonomic ganglia do not use muscarinic M1 receptors exclusively for fast transmission; fast ganglionic transmission is mediated by nicotinic receptors (NN subtype, primarily α3β4), not muscarinic receptors; muscarinic M1 receptors do modulate ganglionic transmission (producing the slow EPSP lasting seconds), but this is slow modulatory transmission, not fast synaptic transmission; hexamethonium blocks the fast nicotinic (not M1) component.
Option B: Option B is incorrect: not all autonomic ganglia use both nicotinic for fast AND muscarinic M1 for slow modulation — while this is correct for some ganglia, postganglionic parasympathetic fibers do not release ACh at M1 receptors on effector organs; they release ACh at M2, M3, M4, or M5 receptors depending on the target tissue; M2 (not M1) mediates cardiac parasympathetic effects; M3 mediates glandular and smooth muscle parasympathetic effects.
Option C: Option C is incorrect: preganglionic sympathetic fibers do not release norepinephrine at autonomic ganglia; they release ACh, which acts at nicotinic receptors on postganglionic neurons; norepinephrine is the postganglionic sympathetic neurotransmitter released at effector organs (with the exception of sweat glands, which are innervated by cholinergic sympathetic fibers); the cholinergic-nicotinic nature of preganglionic transmission is a universal principle for both sympathetic and parasympathetic divisions.
Option D: Option D is partially correct in identifying nicotinic receptors for fast ganglionic transmission in both divisions and ACh at muscarinic receptors on effectors for the parasympathetic division; however, Option E is the correct and most complete answer because it additionally specifies the post-ganglionic sympathetic neurotransmitter (NE at adrenergic receptors) and explicitly distinguishes the effector receptor types, providing the full comparative picture of sympathetic versus parasympathetic transmission from ganglia to effector.

9. The parasympathetic nervous system exerts specific effects on the cardiovascular system through defined muscarinic receptor subtypes. Which of the following correctly describes the muscarinic pharmacology of cardiac regulation, including the ionic mechanism of negative chronotropy?

A) Cardiac parasympathetic innervation acts via M2 receptors on the SA and AV nodes; M2 couples to Gαi, which inhibits adenylyl cyclase (reducing cAMP and reducing I_f pacemaker current) and releases Gβγ subunits that directly activate GIRK channels (IKACh), hyperpolarizing the cell membrane and slowing phase 4 depolarization; both mechanisms reduce heart rate and slow AV conduction; acetylcholine can also reduce atrial contractility through M2-mediated cAMP reduction; ventricular contractility is minimally affected by muscarinic stimulation because ventricular myocardium has sparse parasympathetic innervation.
B) Cardiac parasympathetic innervation acts via M3 receptors on the SA node; M3 couples to Gαq and activates PLC, generating IP₃ which releases Ca²⁺ from the SR, causing calcium-dependent inactivation of L-type calcium channels and slowing pacemaker depolarization; atropine reverses this M3-mediated calcium mechanism, explaining why it increases heart rate in patients with excessive vagal tone.
C) Cardiac parasympathetic stimulation increases heart rate through M1 receptor activation in the SA node; M1 activates Gαq and PKC, which phosphorylates HCN4 (hyperpolarization-activated cyclic nucleotide-gated channel 4) channels directly, increasing I_f and accelerating pacemaker depolarization; the net result of vagal stimulation is paradoxical tachycardia explained by this M1-mediated positive chronotropic mechanism; atropine slows the heart by blocking M1 receptors and removing the vagal tachycardia.
D) M2 receptors are present on ventricular myocardium in high density but are constitutively coupled to Gαs in the basal state; parasympathetic stimulation activates M2, which switches coupling from Gαs to Gαi through receptor phosphorylation; this switching mechanism explains why atropine has no effect on heart rate in transplanted (denervated) hearts where constitutive Gαs coupling is maintained.
E) Parasympathetic cardiac effects are mediated by M4 receptors on the AV node rather than M2; M4 couples to Gαi to slow conduction; M2 receptors at the SA node are irrelevant to chronotropy; the bradycardia produced by edrophonium in the Tensilon test for myasthenia gravis reflects M4 receptor activation at the AV node rather than SA node effects; atropine pretreatment before edrophonium blocks M4 specifically.

ANSWER: A

Rationale:

The cardiac effects of parasympathetic stimulation provide a direct clinical application of M2 receptor pharmacology. The vagus innervates the SA node, AV node, and atrial myocardium predominantly; ventricular parasympathetic innervation is sparse. M2 receptors couple to Gαi/o through two simultaneous effector pathways: (1) Gαi inhibits adenylyl cyclase → reduces cAMP → reduces PKA-dependent phosphorylation of HCN4 (funny channel) → reduced I_f → slower phase 4 pacemaker depolarization → negative chronotropy; (2) Gβγ directly activates the inward rectifier K⁺ channel IKACh (GIRK1/GIRK4 [G protein-coupled inward rectifier potassium channel 1/4] heterotetramer) → increased K⁺ efflux → membrane hyperpolarization → reduces SA node firing rate and slows AV nodal conduction → negative dromotropy. Atropine reverses both effects, increasing heart rate and AV conduction velocity. The minimal effect on ventricular contractility reflects sparse ventricular vagal innervation. Options B, C, D, and E all misidentify receptor subtype, signaling mechanism, or physiological consequence of parasympathetic cardiac stimulation.

Option B: Option B is incorrect: cardiac parasympathetic innervation does not act via M3 receptors at the SA node; M3 is expressed predominantly in smooth muscle and glands, not in cardiac pacemaker cells; the cardiac parasympathetic effect is specifically mediated by M2 receptors; additionally, M3-Gαq-IP3-Ca2+ signaling is a smooth muscle contraction mechanism (not cardiac bradycardia), and calcium-dependent inactivation of If is not the established mechanism for M2-mediated heart rate reduction.
Option C: Option C is partially correct in identifying M1-Gαq-PKC-HCN4 phosphorylation as a mechanism; however, this represents M1 receptor-mediated INCREASE in heart rate (M1 activates PKC which phosphorylates HCN4 increasing If), not the parasympathetic slowing of heart rate; the dominant cardiac parasympathetic chronotropic mechanism is M2-Gαi-GIRK1/4 (IKACh), not M1; Option C is describing the excitatory effect of M1 (found in some ganglia), not the vagal bradycardia mechanism.
Option D: Option D is incorrect: M2 receptors are not constitutively coupled to Gαs in the basal state — this is pharmacologically inaccurate; M2 receptors couple exclusively to Gαi throughout their pharmacological activity; constitutive coupling switching from Gαs to Gαi is not an established mechanism for any muscarinic receptor subtype; the concept of agonist-induced G-protein switching does not apply to M2 in the manner described.
Option E: Option E is incorrect: cardiac parasympathetic effects are not mediated by M4 receptors at the AV node; M4, like M2, couples to Gαi, but the dominant cardiac parasympathetic receptor mediating both SA node slowing and AV nodal conduction slowing is M2; M4 receptors have limited cardiac expression compared to M2; the assignment of SA node chronotropy to M2 and AV node effects to M4 is not consistent with established cardiac autonomic pharmacology.

10. Muscarinic M3 receptors mediate key parasympathetic effects on smooth muscle and exocrine glands. Which of the following correctly describes the M3-mediated signaling cascade responsible for bronchospasm and the pharmacological basis for ipratropium's clinical use in COPD?

A) M3 receptors in airway smooth muscle couple to Gαs, increasing cAMP and activating PKA; PKA phosphorylates myosin light-chain kinase (MLCK), increasing its activity and causing bronchoconstriction; ipratropium blocks this cAMP-PKA-MLCK cascade, producing bronchodilation; the clinical advantage over β₂ agonists is that ipratropium reduces cAMP rather than increasing it, creating a different pharmacological balance.
B) M3 receptors in airway smooth muscle couple to Gαi, reducing cAMP; reduced cAMP allows myosin light-chain phosphatase to dephosphorylate myosin, paradoxically causing bronchoconstriction; ipratropium reverses this by blocking M3, allowing cAMP to rise and myosin phosphatase to remain active; this explains why M3 antagonists and β₂ agonists have additive rather than synergistic bronchodilator effects.
C) M3 receptors in airway smooth muscle couple to Gαq, activating PLCβ to generate IP₃ (releasing Ca²⁺ from SR) and DAG (activating PKC); elevated intracellular Ca²⁺ activates calmodulin-MLCK, phosphorylating myosin regulatory light chains and driving smooth muscle contraction (bronchoconstriction); ipratropium is a quaternary ammonium antimuscarinic that blocks M3 in airway smooth muscle, preventing ACh-mediated bronchoconstriction; its quaternary structure limits systemic absorption and CNS penetration, minimizing atropine-like side effects; in COPD, increased cholinergic tone from the vagus is a major contributor to bronchospasm, making M3 blockade particularly effective.
D) M3 receptors in bronchial smooth muscle are coupled to Gαq but their primary effector is PLD (phospholipase D) rather than PLC; PLD cleaves phosphatidylcholine into phosphatidic acid and choline; phosphatidic acid directly opens plasma membrane Ca²⁺ channels; ipratropium's clinical benefit in COPD is explained by its selective blockade of M3 over M2; M2 blockade would actually worsen bronchospasm by preventing prejunctional feedback inhibition of ACh release, so ipratropium's M3 selectivity is critical to its therapeutic profile.
E) M3 receptors in airway smooth muscle are activated by ACh released from non-neuronal airway epithelial cells rather than from parasympathetic nerve terminals; the receptor couples to Gαq but the relevant downstream effector is phospholipase A₂ rather than PLC; arachidonic acid released by PLA₂ is metabolized to leukotrienes that cause bronchoconstriction; ipratropium prevents this leukotriene cascade by blocking M3, making it more effective than leukotriene antagonists for acute bronchoconstriction in COPD.

ANSWER: C

Rationale:

M3-mediated bronchoconstriction follows the canonical Gαq signaling pathway: M3 receptor activation → Gαq → PLCβ → PIP₂ cleavage → IP₃ + DAG; IP₃ binds IP₃ receptors on the SR → Ca²⁺ release → Ca²⁺-calmodulin → MLCK activation → myosin regulatory light chain phosphorylation → cross-bridge cycling → smooth muscle contraction. In COPD, increased resting cholinergic (vagal) tone contributes substantially to airflow obstruction, making anticholinergic therapy particularly effective. Ipratropium is a quaternary ammonium compound derived from atropine; its permanent charge prevents significant systemic absorption from inhaled administration and limits BBB penetration, greatly reducing atropine-like adverse effects (tachycardia, urinary retention, dry mouth). Note: M2 autoreceptors on parasympathetic nerve terminals provide negative feedback (limit ACh release); non-selective antimuscarinics can block these, potentially worsening bronchoconstriction — tiotropium's long-acting M3 selectivity profile has been studied for this reason. Options A, B, D, and E all contain errors in the M3 signaling cascade, ipratropium mechanism, or COPD pharmacology.

Option A: Option A is incorrect: M3 receptors in airway smooth muscle couple to Gαq (not Gαs); Gαs would increase cAMP, activating PKA which inhibits MLCK — this would produce bronchodilation (the opposite of M3's effect); M3-Gαq signaling produces IP3-mediated Ca2+ release and DAG-PKC activation, increasing MLCK activity and causing smooth muscle contraction (bronchoconstriction).
Option B: Option B is incorrect: M3 receptors couple to Gαq (not Gαi); Gαi would reduce cAMP, but M3-mediated bronchoconstriction is not through cAMP reduction — it is through Gαq-PLC-IP3-Ca2+ signaling; additionally, the mechanism described (Gαi-reduced cAMP allowing MLCP to dephosphorylate myosin causing "paradoxical" bronchoconstriction) misapplies the pharmacology of smooth muscle relaxation versus contraction.
Option D: Option D is incorrect: while PLD (phospholipase D) can be activated by M3 in some smooth muscle types, the primary effector for M3 in airway smooth muscle is PLC (phospholipase C), not PLD; the IP3-Ca2+ pathway from PLC (not phosphatidic acid from PLD) is the dominant mechanism of M3-mediated airway smooth muscle contraction; ipratropium's mechanism specifically targets the M3-PLC-IP3 pathway.
Option E: Option E is incorrect: M3 receptors in airway smooth muscle are activated primarily by ACh from parasympathetic (vagal) nerve terminals and to a lesser extent by ACh from non-neuronal sources; the statement that non-neuronal airway epithelial ACh is the "primary" source rather than parasympathetic nerve terminals misrepresents the dominant pathway; additionally, M3 in airway epithelium does regulate secretion, but bronchomotor tone is primarily neurally regulated through M3 on smooth muscle.

11. Cholinergic signaling at autonomic ganglia involves both fast nicotinic transmission and slower muscarinic modulation. Which of the following correctly describes the synaptic pharmacology of autonomic ganglia, including both fast and slow components, and identifies a drug that exploits this pharmacology?

A) Fast ganglionic transmission is mediated by M1 muscarinic receptors that produce a rapid EPSP lasting 1–2 milliseconds; slow excitatory potentials lasting several seconds are mediated by nAChRs that activate a secondary Ca²⁺ cascade; mecamylamine blocks M1 receptors to produce ganglionic blockade; the fast M1 EPSP is insensitive to hexamethonium because hexamethonium only blocks open nAChR channels and M1 receptors do not form ion channels.
B) Fast ganglionic transmission is mediated by nicotinic α3β4-containing receptors producing a rapid depolarizing EPSP (onset <1 ms, duration 10–50 ms) sufficient to trigger an action potential; slower modulatory potentials include a late slow EPSP mediated by M1 muscarinic receptors (via Gαq-closure of M-type K⁺ channels, lasting seconds) and a slow IPSP (inhibitory postsynaptic potential) mediated by dopamine (in some ganglia); hexamethonium blocks nAChR channels by entering the open channel pore (open-channel block); mecamylamine is a secondary amine ganglionic blocker with CNS penetration used for refractory hypertension and studied for nicotine dependence.
C) Autonomic ganglia lack muscarinic modulation entirely; all ganglionic transmission is mediated exclusively by α7 homomeric nicotinic receptors; hexamethonium is a competitive antagonist at the ACh binding site of α7 receptors; mecamylamine is an open-channel blocker of α7 receptors; this α7-dominant ganglionic pharmacology explains why the cognitive effects of nicotine (also mediated by α7) are blocked by ganglionic blockers at doses effective for autonomic blockade.
D) Fast ganglionic transmission uses nAChRs, but the postsynaptic cell is hyperpolarized rather than depolarized because ganglionic nAChRs are permeable to Cl⁻ rather than Na⁺/K⁺; the resulting IPSP must be overcome by muscarinic M3 stimulation from co-released peptides; hexamethonium prevents ganglionic hyperpolarization and paradoxically increases autonomic outflow by blocking the inhibitory nAChR pathway.
E) Ganglionic nAChRs contain α4 and β2 subunits identical to those in the cortex; this explains why nicotine patches produce autonomic ganglionic stimulation at the same dose that produces cortical arousal; mecamylamine blocks ganglionic α4β2 receptors selectively while having no effect on cortical α4β2, demonstrating that subunit composition alone does not determine drug sensitivity and that post-translational modifications distinguish ganglionic from cortical receptor pharmacology.

ANSWER: B

Rationale:

Autonomic ganglionic transmission has a well-characterized multi-component synaptic pharmacology. The fast EPSP is mediated by nAChRs — in autonomic ganglia these are predominantly heteromeric receptors containing α3 subunits paired with β4 (and to a lesser extent β2) subunits. Activation produces a rapid depolarization that triggers an action potential in the postganglionic neuron. Slower synaptic potentials modulate ganglionic excitability: the late slow EPSP, lasting seconds to minutes, is mediated by M1 muscarinic receptors that close M-type K⁺ channels (KCNQ [Kv7 potassium channel family] channels) via Gαq/11 and IP₃/PKC pathways, increasing excitability. Some ganglia also exhibit dopamine-mediated slow IPSPs. Hexamethonium is a bis-quaternary ammonium compound that blocks ganglionic nAChRs primarily by entering the open channel pore — an open-channel blocker mechanism. Mecamylamine is a tertiary amine that can penetrate the CNS, making it the ganglionic blocker of choice for studying nicotine dependence and for treating refractory hypertension where CNS effects may be tolerated. Options A, C, D, and E all contain errors regarding receptor type, ionic mechanism, subunit composition, or drug mechanism.

Option A: Option A is incorrect: fast ganglionic transmission is not mediated by M1 muscarinic receptors; it is mediated by nicotinic receptors producing a fast EPSP lasting 1–2 milliseconds; M1 receptors mediate the slow EPSP (lasting seconds), not fast transmission; hexamethonium and trimethaphan are nicotinic receptor blockers, not M1 antagonists; their use as ganglionic blockers confirms that fast ganglionic transmission is nicotinic.
Option C: Option C is incorrect: autonomic ganglia do have muscarinic modulation — M1 receptors at autonomic ganglia mediate the slow EPSP (potentiating nicotinic fast transmission) and M2 autoreceptors modulate ACh release; hexamethonium is a channel-blocking antagonist at the nicotinic receptor (it enters the open channel pore), not a competitive antagonist; α7 homomeric receptors are predominantly found in the CNS and some ganglia but are not the exclusive ganglionic nAChR type.
Option D: Option D is incorrect: ganglionic nAChRs hyperpolarize the cell when activated — they are permeable to Na+ and K+ (with some Ca2+ permeability) and their activation produces membrane depolarization (excitatory EPSP), not hyperpolarization; an IPSP requires Cl- influx (GABA-A) or K+ efflux (M2-GIRK), not nAChR-mediated cation influx.
Option E: Option E is incorrect: ganglionic nAChRs do not contain α4β2 subunits identical to cortical nicotinic receptors; ganglionic nAChRs primarily contain α3β4 and α3β2 subunits (type-3 family), while cortical nicotinic receptors are predominantly α4β2 (type-4/2 family); the pharmacological difference between ganglionic and cortical nicotinic receptors is substantial — hexamethonium blocks ganglionic (α3-containing) but not cortical (α4β2) receptors.

12. The cholinergic system in the central nervous system serves distinct functional roles mediated by different receptor types. Which of the following correctly describes the major CNS cholinergic pathways, receptor subtypes, and their clinical relevance?

A) The primary CNS cholinergic pathway originates from the locus coeruleus and projects to the hippocampus and cortex; this pathway exclusively uses M2 muscarinic receptors; degeneration of locus coeruleus cholinergic neurons causes Alzheimer's disease; AChE inhibitors slow disease by restoring norepinephrine (which is co-released with ACh) rather than by enhancing cholinergic transmission at M2 receptors.
B) CNS cholinergic transmission uses only nicotinic α7 receptors; muscarinic receptors are not expressed in the CNS; the cognitive effects of scopolamine (amnesia, confusion) are explained by α7 nicotinic blockade rather than muscarinic antagonism; donepezil improves cognition in Alzheimer's disease by selectively enhancing α7 receptor activation through allosteric potentiation rather than AChE inhibition.
C) The basal forebrain cholinergic neurons (nucleus basalis of Meynert, medial septum) project to cortex and hippocampus via muscarinic M1 pathways only; the degeneration of these pathways in Alzheimer's disease reduces M1-mediated cortical excitation; galantamine works by allosteric potentiation of M1 receptors rather than AChE inhibition; M1 agonists are preferred over AChE inhibitors because they avoid the nicotinic side effects associated with AChE inhibition.
D) The basal forebrain cholinergic system — including the nucleus basalis of Meynert (Ch4, projecting to neocortex), medial septal nucleus (Ch1, projecting to hippocampus), and diagonal band of Broca — provides the major source of cortical and hippocampal cholinergic innervation; both M1 muscarinic receptors (postsynaptic, supporting cortical excitability and synaptic plasticity) and α4β2 and α7 nicotinic receptors (modulating glutamate and other transmitter release) are clinically relevant; degeneration of these pathways is a core feature of Alzheimer's disease; AChE inhibitors (donepezil, rivastigmine, galantamine) enhance ACh availability at both muscarinic and nicotinic receptors; galantamine additionally allosterically potentiates nAChRs; central muscarinic M1 blockade (from drugs like scopolamine or diphenhydramine) produces the cognitive impairment and amnesia of the anticholinergic syndrome.
E) CNS cholinergic pathways originate exclusively from the pontine reticular formation and use nicotinic M-type receptors — a hybrid receptor class that combines features of both muscarinic GPCRs and nicotinic ion channels; these receptors are blocked by both atropine and curare; Alzheimer's disease results from degeneration of pontine M-type receptor-expressing neurons; current AChE inhibitors are ineffective because they enhance ACh at muscarinic and nicotinic receptors but not at the relevant M-type receptors.

ANSWER: D

Rationale:

The CNS cholinergic system, particularly the basal forebrain system, is pharmacologically and clinically critical. Key anatomical components: nucleus basalis of Meynert (NBM [Ch4]) → neocortex (diffuse); medial septum (Ch1) and diagonal band of Broca (Ch2) → hippocampus; these pathways use ACh as their neurotransmitter and regulate cortical arousal, attention, learning, and memory consolidation. Both muscarinic (predominantly M1 postsynaptically) and nicotinic (α4β2 and α7) receptors mediate cholinergic CNS effects: M1 activation increases cortical excitability via closure of M-type K⁺ channels and facilitation of LTP (long-term potentiation); α4β2 nicotinic receptors modulate neurotransmitter release presynaptically (glutamate, dopamine); α7 receptors (high Ca²⁺ permeability) are important for synaptic plasticity and have been proposed as targets in schizophrenia and Alzheimer's. AChE inhibitors used in Alzheimer's (donepezil, rivastigmine, galantamine) enhance ACh at all CNS cholinergic synapses. Galantamine has the additional property of positive allosteric modulation of nAChRs. Central muscarinic blockade (scopolamine, antihistamines with anticholinergic properties, tricyclic antidepressants) produces anticholinergic delirium — amnestic, disoriented, agitated — directly from M1 blockade in cortex and hippocampus. Options A, B, C, and E all contain errors about pathway anatomy, receptor types, mechanism of action, or disease pathology.

Option A: Option A is incorrect: the primary CNS cholinergic pathway does not originate from the locus coeruleus; the locus coeruleus is the principal noradrenergic (NE-releasing) nucleus, not a cholinergic nucleus; the basal forebrain cholinergic system (nucleus basalis of Meynert projecting to cortex, medial septum and diagonal band projecting to hippocampus) is the primary cholinergic system relevant to cognition and Alzheimer's disease.
Option B: Option B is incorrect: CNS cholinergic transmission does not use only α7 nicotinic receptors; the brain expresses multiple muscarinic subtypes (M1 predominantly in cortex and hippocampus, M2 as presynaptic autoreceptors, M4 in striatum) in addition to multiple nicotinic subtypes (α4β2, α7); scopolamine's cognitive effects (amnesia, confusion) are primarily mediated by M1 muscarinic receptor blockade in the cortex and hippocampus, not nicotinic receptors.
Option C: Option C is incorrect: basal forebrain cholinergic neurons project via both muscarinic M1 pathways AND nicotinic pathways; α7 nicotinic receptors in the cortex and hippocampus are important for cognition and are targeted by some Alzheimer's research; the projection uses ACh as the neurotransmitter, which activates both muscarinic (primarily M1 postsynaptically) and nicotinic (α7 and α4β2) receptors at the target; stating that only M1 muscarinic pathways are used misrepresents the receptor pharmacology at the projection terminals.
Option E: Option E is incorrect: CNS cholinergic pathways do not originate exclusively from the pontine reticular formation; the pontine reticular formation does contain cholinergic neurons (pedunculopontine and laterodorsal tegmental nuclei, projecting to the thalamus and involved in REM sleep), but the basal forebrain cholinergic system is the dominant pathway for cortical and hippocampal cholinergic innervation; additionally, "nicotinic M-type receptors combining muscarinic and nicotinic features" is a fabricated receptor class with no pharmacological basis.